TECH Bio-Techne
- 64.520
- +0.460+0.72%
Bio-Techne News
Express News | Bio-Techne Shares Are Trading Higher After the Company Announced a Distribution Agreement With Thermo Fisher Scientific
RBC Capital Adjusts Price Target on Bio-Techne to $71 From $79
Bio-Techne (TECH) has an average buy rating and price target range of $65 to $95, according to analysts polled by Capital IQ. Price: 65.50, Change: +1.44, Percent Change: +2.25
Express News | Bio-Techne Announces New Distribution Agreement With Thermo Fisher Scientific
Express News | Bio-Techne Corp : RBC Cuts Target Price to $71 From $79
BIO-TECHNE AND NOVOMOL-Dx ANNOUNCE POINT-OF-CARE OCULAR BIOMARKER ASSAY
MINNEAPOLIS, April 26, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) and Novomol-Dx, a molecular diagnostics company, are pleased to announce the development of Bio-Marker Pathfinder (BM
Global Market for Exosome Diagnostics, Therapeutics, and Research Tools (2021-2028) Featuring Bio-Techne, Exosomics, and System Biosciences - An Evaluation of New Commercial Opportunities and Emerging Trends
Getting In Cheap On Bio-Techne Corporation (NASDAQ:TECH) Is Unlikely
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") below 16x, you may consider Bio-Techne Corporation (NASDAQ:TECH) as a stock to avoid entirely with its
Navigating 4 Analyst Ratings For Bio-Techne
In the preceding three months, 4 analysts have released ratings for Bio-Techne (NASDAQ:TECH), presenting a wide array of perspectives from bullish to bearish.Summarizing their recent assessments, the
Bio-Techne Price Target Cut to $82.00/Share From $85.00 by Deutsche Bank
Bio-Techne Price Target Cut to $82.00/Share From $85.00 by Deutsche Bank
Bio-Techne Is Maintained at Buy by Deutsche Bank
Bio-Techne Is Maintained at Buy by Deutsche Bank
Bio-Techne Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/18/2024 28.97% Deutsche Bank $85 → $82 Maintains Buy 02/02/2024 2.23% Stifel → $65 Downgrades Buy → Hol
Express News | Bio-Techne Corp : Deutsche Bank Cuts Target Price to $82 From $85
Cardinal Health, Cigna, Merck Among Top Healthcare Quant Picks Ahead of Q1 Earnings
BIO-TECHNE TO HOST CONFERENCE CALL ON MAY 1, 2024, TO ANNOUNCE THIRD QUARTER FISCAL 2024 FINANCIAL RESULTS
MINNEAPOLIS, April 10, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Wednesday, May 1, 2024, at 8:00 a.m. CDT t
RBC Capital Reaffirms Their Hold Rating on Bio-Techne (TECH)
RBC Raises Price Target on Bio-Techne to $79 From $75, Keeps Sector Perform Rating
Bio-Techne (TECH) has an average investment rating of buy among analysts polled by Capital IQ, with price targets ranging from $65 to $95.
BIO-TECHNE SURPASSES 10,000 PEER-REVIEWED PUBLICATIONS CITING RNAscope TECHNOLOGY
Bio-Techne Corporation (NASDAQ: TECH) today announced that Advanced Cell Diagnostics (ACD), part of Bio-Techne's Spatial Biology Division, has...
Bio-Techne Corporation (NASDAQ:TECH) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?
Bio-Techne (NASDAQ:TECH) has had a rough month with its share price down 9.4%. However, a closer look at its sound financials might cause you to think again. Given that fundamentals usually drive lo
BIO-TECHNE TO PRESENT AT THE 2024 AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) CONFERENCE
Bio-Techne Corporation (NASDAQ:TECH) today announced it will showcase its portfolio of solutions to advance cancer research from target discovery to...
BIO-TECHNE RECEIVES CiteAb'S ELISA KIT SUPPLIER OF THE YEAR AND SPATIAL BIOLOGY INNOVATION AWARDS
Bio-Techne Corporation (NASDAQ: TECH), a leading provider of innovative tools and bioactive reagents for the research and clinical diagnostic...
Analysis
Price Target
No Data
